The global human microbiome market is expected to reach US$ 1,197.08 Mn in 2025 from US$ 257.30 Mn in 2017. The market is estimated to grow with a CAGR of 21.8% from 2018-2025. The increasing incidence of lifestyle diseases are expected to fuel the market growth during the forecast period.As per World health organization in 2016, 13% of the world population (adults) were obese.
According to the "The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation" published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ, whose composition and functionality contribute to the development of obesity.However, the strict government guidelines is the major concern in the human microbiome market.
The strict government guidelines are intended to hamper the market to an extent.The advancements in science and technology made the scientists excited about the potential and potency of fecal matter and the microbes in it.
The cell-based therapies found a novel paradigm in drug development, a regulatory framework that reports safety and bio containment issues should be established to minimize adverse events and environmental release of engineered organisms. In recent years, for drug discovery the microbiota plays an important role in the efficacy of therapeutic compounds. There is a new phenomenon in the globe. It is the human gut microbiome and the role it may play in the future of human health. Recently various reports have indicated that the human gut microbiome may be implicated in health conditions such as obesity, metabolism, diabetes, immunity and autism. The product segment of the human microbiome market is broadly segmented into food, medical foods, probiotics, prebiotics, drugs, diagnostic devices and supplements.In 2017, the probiotics segment held the largest share of the market, by product.
However, the prebiotics is expected to grow at the fastest CAGR during the forecast period owing to growing demand for fiber rich food products is expected to drive the market. Additionally, rising investment in the food & beverage industry for innovation and development of new food products enriched with prebiotics. The application segment of the human microbiome market is broadly segmented into diagnostics and therapeutics.In 2017, therapeutics segment held the largest share of the market, by application.
Moreover, the therapeutics segment is expected to grow at the fastest rate during the coming years owing to the increase in digestive problems, increase in the drug-related side effects, and development of therapies for chronic diseases like cancer. Some of the major primary and secondary sources included in the report for the human microbiome market are National Cancer Institute, National Health Service, World Health Organization, Food and Drug Administration, Public Health England, and Health Protection Agency among others.
Reasons to Buy Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the human microbiome market. Highlights key business priorities in order to assist companies to realign their business strategies. The key findings and recommendations highlight crucial progressive industry trends in the global human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies. Develop/modify business expansion plans by using substantial growth offering developed and emerging markets. Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it. Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Our reports have been used by over 10K customers, including:
The anatomic pathology market is projected to reach US$ 33,145.78 million by 2028 from US$ 21,488. 41 million in 2021; it is estimated to grow at a CAGR of 6.4% from 2021 to 2028. Factors such as increase in the prevalence of cancer and other diseases, and growing focus on personalized medicines. However, the lack of skilled professionals...
The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on...
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021-2028. The market growth is mainly attributed to factors such as the increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing...
Best foot forward: Revenue will likely rise as more healthcare providers stress the importance of preventive care Abstract Podiatrists in the US Over the five years to 2019, the Podiatrists industry has stepped in the right direction. Revenue growth has been supported by the aging US population and...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
17 pages •
By Euromonitor International
• Oct 2020
A combination of natural increase and positive net migration will drive population growth in Ireland up to 2040. Ageing will continue to be a key demographic trend, though Ireland will remain relatively young in a regional context due to comparatively high birth rates. Longevity will continue to improve, but certain health issues will rise...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.